Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Placebo Clear all

Conditions: Kidney Failure
Interventions: rhC1INH, Saline Solution; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Major Depressive Disorder
Interventions: Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Cognitive Remediation, Computer Games; Behavioral
Lead sponsor: Wesleyan University; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Hartford, Connecticut • Middletown, Connecticut

Conditions: Frailty
Interventions: Magnetic Mitohormesis Therapy; Other
Lead sponsor: Auburn University; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Breast Cancer, Non-Hodgkin's Lymphoma
Interventions: Mesna, Saline, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Human Health, Reactive Carbonyl Species, Polyphenols
Interventions: Soymilk, green tea, or blueberry, Control group; Dietary Supplement
Lead sponsor: North Carolina Agriculture & Technical State University; Other
Eligibility: 25 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Prostate Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement; Procedure · Drug · Dietary Supplement
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more

Conditions: Hypoglycemia Unawareness
Interventions: Carvedilol 3.125 mg, Carvedilol 2.5 mg, Placebo capsule; Drug
Lead sponsor: Owen Chan, PhD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Dental Pain and Sensation Disorder, Pain, Postoperative
Interventions: Gabapentin 600mg, Placebo; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 7 Months
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more

Conditions: Peripheral Arterial Disease
Interventions: Walking assessment, QOL Survey, Ankle pressure at rest and after stress, Muscle Oxygen, Serum MitoQ Level, Needle Biopsy; Diagnostic Test · Other · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Healthy
Interventions: nikkomycin Z; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 40 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Enterovirus Infection
Interventions: EV68-228-N, Placebo for EV68-228-N; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Baltimore, Maryland • Nashville, Tennessee

Conditions: Dysgeusia
Interventions: mBerry, No intervention; Dietary Supplement · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Heart Arrest, Out-Of-Hospital, Opioid Overdose, Naloxone
Interventions: Naloxone 2 MG, Saline 2ml; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: AIS
Interventions: NBP Softgel Capsules, Placebo; Drug
Lead sponsor: CSPC-NBP Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 21
States / cities: Los Angeles, California • Jacksonville, Florida • Des Moines, Iowa + 15 more

Conditions: Pain
Interventions: Real acupuncture, Sham acupuncture, VGAIT, VGAIT control; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Cardiovascular Diseases
Interventions: Rhamnan sulfate; Dietary Supplement
Lead sponsor: University of Texas at Austin; Other
Eligibility: 35 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Interventions: Satralizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more

Conditions: Burn Scars
Interventions: Pulse-Dye Laser, Sham; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 9 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions: Nicotinamide Riboside, Placebo, Exercise Intervention; Dietary Supplement · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years to 30 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee

Conditions: Accidental Falls
Interventions: Tailored home intervention, Sham intervention; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Spinal Cord Injuries, Skeletal Muscle Atrophy, Metabolic Disease
Interventions: Neuromuscular electrical stimulation; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Central Nervous System Carcinoma
Interventions: Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 4 Years to 17 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 137
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more

Search by objective public record fields.

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

Comparing Cognitive Remediation Approaches for Schizophrenia

Pilot-testing the Effect of Magnetic Mitohormesis Therapy for Treating Frailty in Older Adults

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

Scavenging of Reactive Carbonyl Species by Dietary Flavonoids in Humans

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Carvedilol in Treating Hypoglycemia Unawareness

Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

Safety and PK of Nikkomycin Z in Healthy Subjects

Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults

Effects of Flavor Modification for Management of Radiation Induced Dysgeusia

Naloxone for Opioid Associated Out of Hospital Cardiac Arrest

NBP in Adult Patients With Acute Ischemic Stroke (AIS)

Mechanistic Studies on Video-guided Acupuncture Imagery Treatment of Pain

Seaweed-derived Rhamnan Sulfate and Vascular Function

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Laser Therapy for Treating Hypertrophic Burn Scars in Children

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

The Effectiveness of a Fall Prevention Program

Metabolic Health in Individuals With Spinal Cord Injury (SCI)

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor